VISION
2021
177Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
In 831 patients with PSMA-positive mCRPC after androgen-receptor signalling inhibition and taxane chemotherapy, 177Lu-PSMA-617 + standard care improved radiographic PFS and overall survival compared with standard care alone.
Result
Efficacy: rPFS and OSHR 0.62
Below 1 favours 177Lu-PSMA-617 + standard care, above 1 favours standard care alone.
Event rates 177Lu-PSMA-617 + standard care 15.3 vs standard care alone 11.3 months
Also reported: rPFS HR 0.40;
- Subtopic
- mCRPC PSMA-RLT
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Sartor O, et al. N Engl J Med. 2021;385(12):1091-1103.doi 10.1056/NEJMoa2107322
Discussion & critique
First radioligand therapy with an OS benefit in heavily pretreated mCRPC. PSMA PET–based patient selection is essential.